Ranbaxy Q4: Co Allays U.S. FDA Fears
  • Prabha Hedge
  • Feb 05 2014

February 5: Ranbaxy's fourth quarter revenues and margins have come in-line with street estimates. Also, commentary from the management on the U.S. FDA ban at Toansa has boosted the stock. The management allayed fears regarding the U.S. FDA ban on their Toansa facility. Agam Vakil and Priya Sheth share more details on the company’s Q4 results and the management commentary.